Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Seer, Inc.NASDAQ: SEER

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $1.53M fell 4.4% year over year, ahead of the -22.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 323.0% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.

Context

  • Depreciation & amortization amounted to 44.9% of revenue in FY2025, up 0.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -4.4% holds above the trailing-twelve-month pace of -22.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.53M+323.0% QoQ
Last fiscal yearDec 2025
$7.25M+17.3% YoY
LTMMar 2026
$4.89M-22.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%——
1 year+17.3%——
3-year CAGR+22.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
7.25M USD
Year-over-year change
+17.3%
4-year CAGR
+29.7%

Depreciation & Amortization vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.2% is the 16th highest of 18, against a peer median of +0.8%.
  • Depreciation & amortization amounts to 32.5% of revenue for SEER, versus a peer median of 10.1%.
SEER Competitors
Depreciation & Amortization for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$15.87M USD-14.3%+20.4%2.3%
SANASana Biotechnology, Inc.LTM Mar 2026$11.5M USD-33.5%-6.6%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
NKTXNkarta, Inc.LTM Mar 2026$8.74M USD-5.0%+20.5%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$8.34M USD+0.8%+30.7%19.4%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$8.23M USD+1.6%+40.8%7.8%
SEERSeer, Inc.LTM Mar 2026$4.89M USD-22.2%+22.5%32.5%
QSIQuantum-Si incorporatedLTM Mar 2026$4.76M USD+6.9%+19.9%257.1%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.38M USD+84.9%+5.3%9.7%
PEPGPepGen Inc.LTM Mar 2026$3.2M USD-5.6%+118.5%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$2.84M USD-8.0%-25.0%10.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.37M CHF+2.1%-3.5%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.19M USD+3.5%+8.1%—
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$314K USD+2.6%+49.5%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$154K USD+170.2%——
MNOVMediciNova, Inc.LTM Mar 2026$19.18K USD-8.2%+4.3%3.2%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding SEER) —+0.8%+14.0%10.1%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.